Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva’s anti-IL-15 candidate, TEV-‘408 ...
Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary, unaudited select ...
The company reminds us that a great customer experience isn’t complicated. And as important as anything, they don’t just ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback